Surgical management of diabetic retinopathy

Vishali Gupta, J Fernando Arevalo, Vishali Gupta, J Fernando Arevalo

Abstract

Surgery for late complications of proliferative diabetic retinopathy remains the cornerstone of management even in patients who have received optimal laser photocoagulation and medical therapy. With improvisation in the surgical techniques and development of micro-incision surgical techniques for vitrectomy, the indications for surgical intervention are expanding to include diabetic macular edema with a greater number of patients undergoing early intervention. This review describes the current indications, surgical techniques, adjunctive anti-vascular endothelial growth factor therapy, surgical outcomes, and postoperative complications of pars plana vitrectomy for proliferative diabetic retinopathy and macular edema.

Keywords: Diabetic Macular Edema; Diabetic Retinopathy; Pars Plana Vitrectomy; Proliferative Diabetic Retinopathy.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Color fundus photograph of the right eye showing fibrovascular proliferation extending from nasal half of the optic disc to the fovea causing macular pucker. The patient underwent 23-gauge transconjuctival pars plana vitrectomy
Figure 2
Figure 2
Same eye as in Figure 1, 3 months later showing release of traction over the fovea with normal foveal contour
Figure 3
Figure 3
Color photograph of the left eye showing tractional retinal detachment. The patient underwent 23-gauge transconjunctival pars plana vitrectomy
Figure 4
Figure 4
Same eye as in Figure 3, 2 months postoperatively, showing a flat retina. The best corrected visual acuity improved from 20/200 to 20/40 postoperatively

References

    1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XII: The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–15.
    1. Arnos AF, McCarty DJ, Zimmett P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med. 1997;14:S1–85.
    1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: Diabetic macular edema. Ophthalmology. 1984;91:1464–74.
    1. Gotzaridis EV, Lit ES, D’Amico DJ. Progress in vitreoretinal surgery for proliferative diabetic retinopathy. Semin Ophthalmol. 2001;16:31–40.
    1. Gupta V, Gupta A, Dogra MR, Singh R. Diabetic Retinopathy Atlas and text. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2007. pp. 75–88.
    1. DCCT Research Group. The effect of intensive treatment of diabetes in the development and progression of long-term complication in insulin-dependent diabetes. N Engl J Med. 1993;329:977–86.
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive-blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;317:703–13.
    1. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976;81:383–96.
    1. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of Diabetic macular edema. Am J Ophthalmol. 2004;137:675–82.
    1. Evoy KE, Abel SR. Ranibizumab: The first endothelial growth factor inhibitor approved for the treatment of diabetic macular edema. Ann Pharmacother. 2013;47:811–8.
    1. Abu-El-Asrar AM, Al-Mezaine HS. Advances in the treatment of diabetic retinopathy. Discov Med. 2010;9:363–73.
    1. Machemer R, Buettner H, Norton RWD, Parel JM. Vitrectomy in the management of severe diabetic retinopathies. Trans Am Acad Ophthalmol Otolayngol. 1971;75:813–20.
    1. Flynn HW, Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL., 3rd Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992;99:1351–7.
    1. Smiddy WE, Flynn HW., Jr Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol. 1999;43:491–507.
    1. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology. 1985;92:492–502.
    1. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol. 1990;108:958–64.
    1. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol. 1985;103:1644–52.
    1. Gupta B, Sivaprasad S, Wong R, Laidlaw A, Jackson TL, McHugh D, et al. visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: The Drive UK study. Eye (Lond) 2012;26:510–6.
    1. Goldenberg DT, Hassan TS. Small gauge, sutureless surgery techniques for diabetic vitrectomy. Int Ophthalmol Clin. 2009;49:141–51.
    1. Scalon PH. Why do patients still require surgery for the late complications of proliferative diabetic retinopathy? Eye (Lond) 2010;24:435–40.
    1. Landers MB, Perraki AD. Management of post-vitrectomy persistent vitreous hemorrhage in pseodophakia eyes. Am J Ophthalmol. 2003;136:989–93.
    1. Packer AJ. Vitrectomy for progressive macular traction associated with proliferative diabetic retinopathy. Arch Ophthalmol. 1987;105:1679–82.
    1. Canan H, Sizmaz S, Altan-Yaycioglu R. Surgical results of combined pars plana vitrectomy and phacoemulsification for vitreous hemorrhage in PDR. Clin Ophthalmol. 2013;7:1597–601.
    1. Thompson JT, Bustrop S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of macula. Arch Ophthalmol. 1987;105:497–502.
    1. Yang CM, Su PY, Yeh PT, Chen MS. Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: Clinical manifestations and surgical outcome. Can J Ophthalmol. 2008;43:192–8.
    1. Grigorian RA, Castellarin A, Bhagat N, Del Priore L, Von Hagen S, Zarbin MA. Use of viscodissection and silicone oil in vitrectomy for severe diabetic retinopathy. Semin Ophthalmol. 2003;18:121–6.
    1. Grigorian RA, Castellarin A, Fegan R, Seery C, Del Priore LV, Von Hagen S, et al. Epiretinal membrane removal in diabetic eyes: Comparison of viscodissection with conventional methods of membrane peeling. Br J Ophthalmolgy. 2003;87:737–41.
    1. Castellarin A, Grigorian RA, Bhagat N, Del Priore L, Zarbin MA. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol. 2003;87:318–21.
    1. O’Hanley GP, Canny CL. Diabetic dense premacular hemorrhage: A possible indication for prompt vitrectomy. Ophthalmology. 1985;92:507–11.
    1. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction. Ophthalmology. 1982;99:753–9.
    1. Harbour JW, Smiddy WE, Flynn HW, Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with taut posterior hyaloids membrane. Am J Ophthalmol. 1996;121:405–13.
    1. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomized controlled feasibility trial of vitrectomy versus laser for diabetic macular edema. Br J Ophthalmol. 2005;89:81–6.
    1. Patel JI, Hykin PG, Schadt M, Luong V, Bunce C, Fitzke F, et al. Diabetic macular edema: Pilot randomized trial of pars plana vitrectomy vs macular argon photocoagulation. Eye (Lond) 2006;20:873–81.
    1. Gentile RC, Milman T, Eliott D, Romero JM, McCormick SA. Taut internal limiting membrane causing diffuse diabetic macular edema after vitrectomy: Clinicopathological correlation. Ophthalmologica. 2011;226:64–70.
    1. Yanali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu AF. Pars plana vitrectomy and removal of internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol. 2006;16:573–81.
    1. Mason JO, 3rd, Colagross CT, Vail R. Diabetic vitrectomy: Risks, prognosis, future trends. Curr Opin Ophthalmol. 2006;17:281–5.
    1. Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina. 2006;26:5–13.
    1. Hartlet KL, Smiddy WE, Flynn HW, Jr, Murray TG. Pars plana vitrectomy with internal membrane peeling for diabetic macular edema. Retina. 2008;28:410–9.
    1. Dehghan MH, Salehipour M, Naghib J, Babaeian M, Karimi S, Yaseri M. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse macular edema. J Ophthalmic Vis Res. 2010;5:162–7.
    1. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcome of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557–66.
    1. Yamamoto T, Takeuchi S, Sato Y, Yamashita H. Long-term follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn J Ophthalmol. 2007;51:285–91.
    1. Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N. Long-term follow up of vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2009;29:464–72.
    1. Park JH, Woo SJ, Ha YJ, Yu HG. Effect of vitrectomy on macular microcirculation in patients with diffuse diabetic macular edema. Grafes Arch Clin Exp Ophthalmol. 2009;247:1009–17.
    1. Hoerauf H, Brüggemann A, Muecke M, Lüke J, Müller M, Stefánsson E, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloids removal. A prospective randomized trial. Arch Clin Exp Ophthalmol. 2011;249:997–1008.
    1. Kanski JJ, Gregor ZJ. Retinal detachment: A color Manual of Diagnosis and treatment. Butterworth Heinemann. 1994:160–162.
    1. Canny CL, O’Hanley GP, Wells GA. Pars plana vitrectomy for complications of diabetic retinopathy: Report of 131 cases. Can J Ophthalmol. 1985;20:11–5.
    1. Miller SA, Butler JB, Myers FL, Bresnick GH. Pars plana vitrectomy. Teartment for tractional macula detachment secondary to proliferative diabetic retinopathy. Arch Ophthalmol. 1980;98:659–64.
    1. Gafencu O. Surgical principles and techniques in severe proliferative diabetic retinopathy. Oftalmologia. 2001;52:54–7.
    1. Arevalo JF. En bloc perfluorodissection for tractional retinal detachment in proliferative diabetic retinopathy. Ophthalmology. 2008;115:21–5.
    1. Gupta B, Wong R, Sivaprasad S, Williamson TH. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye (Lond) 2012;26:576–82.
    1. Altan T, Acar N, Kapran Z, Unver YB, Ozdogan S. Transconjunctival 25-gauge sutureless vitrectomy and silicone oil injection in diabetic reinal detachment. Retina. 2008;28:1201–6.
    1. Sato T, Emi K, Bando H, Ikeda T. Faster recovery after 25-gauge microincision vitrectomy surgery than after 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Clin Ophthalmol. 2012;6:1925–30.
    1. Lee JY, Jeong HS, Lee DY, Sohn HJ, Nam DH. Early postoperative intraocular pressure stability after combined 23-gauge sutureless vitrectomy and cataract surgery in patients with proliferative diabetic retinopathy. Retina. 2012;32:1767–74.
    1. Ozone D, Hirano Y, Ueda J, Yasukawa T, Yoshida M, Ogura Y. Outcome and complications of 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Ophthalmologica. 2011;226:76–80.
    1. Issa SA, Conor A, Habib M, Steel DH. Comparison of retinal breaks observed during 23 gauge transconjunctival vitrectomy versus conventional 20 gauge surgery for proliferative diabetic retinopathy. Clin Ophthalmol. 2011;5:109–14.
    1. Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol. 1994;87:223–32.
    1. Kamura Y, Sato Y, Deguchi Y, Yagi F. Iatrogenic retinal breaks during 20-gauge vitrectomy for proliferative diabetic retinopathy. Clin Ophthalmol. 2013;7:29–33.
    1. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative retinopathy (PDR) Grafes Arch Clin Exp Ophthalmol. 2008;246:837–42.
    1. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 2008;146:211–7.
    1. da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, et al. Intraoperative bleeding during vitrectomy for diabetic tractional detachment with versus without preoperative intravitreal bevacizumab. Br J Ophthalmol. 2009;93:688–91.
    1. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927–38.
    1. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2009;19:848–52.
    1. Gupta A, Bansal R, Gupta V, Dogra MR. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single postoperative injection of intravitreal bevacizumab. Int Ophthalmol. 2012;32:135–44.
    1. Ushida H, Kachi S, Asami T, Ishikawa K, Kondo M, Terasaki H. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy. Ophthalmic Res. 2013;49:30–6.
    1. Sato T, Morita S, Bando H, Sato S, Ikeda T, Emi K. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20:51–5.
    1. Jirawison C, Ittipunkul N. Intravitreal bevacizumab at the end of diabetic vitrectomy for prevention of postoperative vitreous hemorrhage: A comparative study. J Med Assoc Thai. 2012;95:136–42.
    1. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29:768–74.
    1. Nakao S, Ishikawa K, Yoshida S, Kohno R, Miyazaki M, Enaida H, et al. Altered vascular microenviornment by bevacizumab in diabetic fibrovascular membrane. Retina. 2013;33:975–63.
    1. Foulks GN, Thoft RA, Perry HD, Tolentino FI. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch Ophthalmol. 1979;97:1076–8.
    1. Oyakawa RT, Schachat AP, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. Intraoperative complications. Ophthalmology. 1983;90:517–21.
    1. Garcia-Valenzuela E, Abdelsalam A, Eliott D, Pons M, Iezzi R, Puklin JE, et al. Reduced need for corneal epithelial debridement during vitreo-retinal surgery using two different viscous surface lubricants. Am J Ophthalmol. 2003;136:1062–6.
    1. Abrams GW, William GA. En bloc excision of diabetic membranes. Am J Ophthalmol. 1987;103:302–8.
    1. Carter JB, Michels RG, Glaser BM, De Bustros S. Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology. 1980;97:848–54.
    1. Qamar RM, Saleem MI, Saleem MF. The outcomes of pars plana vitrectomy without tamponade for tractional retinal detachment secondary to diabetic retinopathy. Malays J Med Sci. 2013;20:55–60.
    1. Jaffe GJ, Lewis H, Han DP, Williams GA, Abrams GW. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Am J Ophthalmol. 1989;108:170–5.
    1. Williams DF, Bennett SR, Abrams GW, Han DP, Mieler WF, Jaffe GJ, et al. Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. Am J Ophthalmol. 1990;109:606–7.
    1. Han DP, Lewis H, Lambrou FH, Jr, Mieler WF, Hartz A. Mechanism of elevated intraocular pressure elevation after pars plana vitrectomy. Ophthalmology. 1989;96:1357–62.
    1. Haimann MH, Abrams GW. Prevention of lens opacification during diabetic vitrectomy. Ophthalmology. 1984;91:116–21.
    1. Hutton WL, Pesicka GA, Fuller DG. Cataract extraction in the diabetic eye after vitrectomy. Am J Ophthalmol. 1987;104:1–4.
    1. Smiddy WE, Stark WJ, Michels RG, Maumenee AE, Terry AC, Glaser BM. Cataract extraction after vitrectomy. Ophthalmology. 1987;94:483–7.
    1. Aaberg TM. Clinical results in vitrectomy for diabetic traction retinal detachment. Am J Ophthalmology. 1979;88:246–53.
    1. Rice TA, Michels RG, Maguire MG, Rice EF. The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 1983;95:1–11.
    1. Blankenship GW. The lens influence on diabetic vitrectomy results: Report of a prospective randomized study. Arch Ophthalmol. 1980;98:2196–8.
    1. Lee MS, Elliott D, Rastogi S, et al. Incidence of rubeosis after vitrectomy for proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1998;39:674.
    1. Helbig H, Kellner U, Bornfeld N, Foerster MH. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1998;236:730–3.
    1. Andriievic-Derk B, Vatavuk Z, Bencic G, Novak-Laus K, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma. Acta Clin Croat. 2008;47:175–9.
    1. Salman AG. Intrasilicone bevacizumab injection for iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Ophthalmic Res. 2013;49:20–4.
    1. Yang CM. Surgical treatment for diabetic retinopathy: 5 year experience. J Formos Med Assoc. 1998;97:477–84.
    1. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91:1485–9.
    1. Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy II Postoperative complications. Ophthalmology. 1983;90:522–30.
    1. Park DH, Shin JP, Kim SY. Comparison of clinical outcomes between 23-gauge and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Retina. 2010;30:1662–70.
    1. Khuthaila MK, Hsu J, Chiang A, DeCroos FC, Milder EA, Setlur V, et al. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol. 2013;155:757–63. 763e1–2.
    1. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710–5.
    1. Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: An ultrasound biomicroscopy study. Ophthalmology. 2005;112:2095–102.
    1. Entezari M, Ramezani A, Ahmadieh H. Cryotherapy of sclerotomy sites for prevention of late post-vitrectomy diabetic hemorrhage: A randomized clinical trial. Grafes Arch Clin Exp Ophthalmol. 2010;248:13–9.
    1. Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H. Can a preoperative bevacizumab injection prevent recurrent post vitrectomy vitreous hemorrhage? Eye (Lond) 2009;23:1698–701.
    1. Ahmadieh H, Shoeibi N, Entrezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early post vitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology. 2009;116:1943–8.
    1. Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H. Can a preoperative bevacizumab injection prevent recurrent post vitrectomy vitreous hemorrhage? Eur J Ophthalmol. 2009;19:618–21.
    1. Guthrie G, Hall AB, Dhalla K, Davis RM, Steel DH. Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa. Eye. 2013 Aug 16; doi: 101038/eye2013182.
    1. Lewis H, Aaberg TM, Abrams GW, et al. Causes of failure after diabetic vitrectomy. Invest Ophthalmol Vis Sci. 1998;20:220.
    1. Lewis H, Aaberg TM, Williams GA. Anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol. 1987;104:607–10.
    1. Kreiger AE. Wound complications in pars plana vitrectomy. Retina. 1993;13:335–44.
    1. Kreiger AE, Straatsma BR, Foos RY. Incisional complications in pars plana vitrectomy. Mod Probl Ophthalmol. 1977;18:210–23.
    1. Koch FH, Kreiger AE, Spitznas M, Glasgow B, Foos RY, Yoshizumi MO. Pars plana incisions of four patients: Histopathology and electron microscopy. Br J Ophthalmol. 1995;79:486–93.
    1. Kobayashi T, Machida S, Fujiwara T, Ishibe T, Kurosaka D. Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovascular proliferation. Clin Ophthalmol. 2010;20:1043–6.
    1. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95:1335–9.
    1. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyloidal traction. Ophthalmology. 1992;99:753–9.
    1. Harbour JW, Smiddy WE, Flynn HW, Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with thickened and taut posterior hyaloids membrane. Am J Ophthalmol. 1996;121:405–13.
    1. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126–33.
    1. Kalvoda J, Duskova J, Kovarik Z, Kubena A, Kalvodova B. Efficiency of vitrectomy in diabetic macular edema and morphometry of surgically removed of the internal limiting membrane. Cesk Slow Oftalmol. 2010;66:76–82.
    1. Diabetic Retinopathy Clinical Research Network Writing Committee. Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087–93.
    1. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic retinopathy clinical research network. Retina. 2010;30:1488–95.
    1. Bahadir M, Ertan A, Mertoglu O. Visual acuity comparison of vitrectomy with and without internal liiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol. 2005;26:3–8.
    1. Yamamoto S, Yamamoto T, Ogata K, Hoshino A, Sato E, Mizunoya S. Morphological and functional changes of the macula after vitrectomy and creation of posterior vitreous detachment in eyes with diabetic macular edema. Doc Ophthalmol. 2004;109:249–53.
    1. Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ. Pars plana vitrectomy for diabetic macular edema: OCT and functional correlations. Eye (Lond) 2006;20:674–80.
    1. Yamada Y, Suzuma K, Kumagami T, Fujikawa A, Kitaoka T. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Ophthalmologica. 2013;229:142–6.
    1. Chhablani JK, Kim JS, Cheng L, Kozak I, Freeman W. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Grafes Arch Clin Exp Ophthalmol. 2012;250:1415–20.
    1. Murakami T, Nishijima K, Akagi T, Uji A, Horii T, Ueda-Arakawa N, et al. Segmentation analysis of retinal thickness after vitrectomy in diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53:6668–74.
    1. Yoshikawa M, Murakami T, Nishijima K, et al. Macular migration towards the optic disc after inner limiting membrane peeling for diabetic macular edema. Invest Ophthalmol Vis Sci. 2013;54:629–35.
    1. Sonoda KH, Sakamoto T, Enaida H, Miyazaki M, Noda Y, Nakamura T, et al. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreal triamcilone acetonide. Ophthalmology. 2004;111:226–30.
    1. Russell SR, Hageman GS. Optic disc, foveal and extrafoveal damage due to surgical separation of the vitreous. Arch Ophthalmol. 2001;119:1653–8.
    1. Haritoglou c, Ehrt O, gass CA, Kristin N, Kampik A. paracentral scotomas: A new finding after vitrectomy for idiopathic macular hole. Br J Ophthalmol. 2001;85:231–3.
    1. Sebag J. Pharacological vitreolysis. Retina. 1998;18:1–3.
    1. Uemura A, Nakamura M, Kachi S, Nishizawa Y, Asami T, Miyake Y, et al. effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch Ophthalmol. 2005;123:209–13.
    1. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol. 2002;240:56–62.
    1. Takano A, Hirata A, Inomata Y, Kawaji T, Nakagawa K, Nagata S, et al. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am J Ophthalmol. 2005;140:654–60.
    1. Baramova EN, Bajou K, Remacle A, L’Hoir C, Krell HW, Weidle UH, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997;405:157–62.
    1. Sakuma T, Tanaka M, Inoue J, Mizota A, Souri M, Ichinose A. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol. 2006;6:138–40.
    1. Azzolini C, D’Angelo A, Maestranzi G, Codenotti M, Della Valle P, Prati M, et al. Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol. 2004;138:560–6.
    1. Asami T, Terasaki H, Kachi S, Nakamura M, Yamamura K, Nabeshima T, et al. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology. 2004;111:231–7.
    1. Hirata A, Takano A, Yonemura N, Sagara N, Tanihara H. Plasmin-associated vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: A pilot study. Retina. 2007;27:1074–8.
    1. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: The MIVI I trial. Ophthalmology. 2009;116:1349–55. 1355e1–2.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa